Research programme: bispecifc antibody therapeutics - BJ Bioscience
Latest Information Update: 01 Oct 2021
Price :
$50 *
At a glance
- Originator BJ Bioscience
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Cancer
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 22 Sep 2021 Research programme: bispecifc antibody therapeutics - BJ Bioscience is available for licensing in World as of 22 Sep 2021. http://www.bjbioscience.com/847469.html
- 22 Sep 2021 Preclinical trials in Cancer in China (Parenteral), before September 2021 (BJ Bioscience website, September 2021)